N/A N=21 Calcitonin for Treating X-linked Hypophosphatemia
Hypophosphatemic Rickets, X Linked Dominant
Primary: Area Under the Curve for FGF23 — 3172.34; 3215.34 pg/ml*hr
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=16 Calcitriol Monotherapy for X-Linked Hypophosphatemia
X-linked Hypophosphatemia · Hypophosphatemic Rickets · Hypophosphatemic Rickets, X-Linked Dominant
Primary: Change in Serum Phosphate in Adults and Children With XLH Between Baseline and 12 Months — 2.6; 2.1 mg/dl — p=0.318
Phase 3 N=33 Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets
Hypophosphatemia, Familial · Hyperparathyroidism
Primary: Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement — 1223; 1449; 987; 1616 nlEq*26hr/ml — p=0.007
Phase 2 N=29 A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
X-linked Hypophosphatemia
Primary: Safety and Efficacy of Repeated SC Injections of KRN23 — 24; 1; 1; 0 Participants
Phase 3 N=134 Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
X-linked Hypophosphatemia
Primary: Percentage of Participants Achieving Mean Serum Phosphorus Levels Above the LLN (2.5 mg/dL [0.81 mmol/L]) at the Mid-Point of the Dose Interval, as Averaged Across Dose…
Phase 3 N=14 Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
X-linked Hypophosphatemia
Primary: Percent Change From Baseline in OV/BV at Week 48 — -54.18 percentage change of unmineralized bone — p=< 0.0001
Phase 2 N=23 An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
X-linked Hypophosphatemia
Primary: Safety and Efficacy of Repeated SC Injections of KRN23. — 21; 1; 1; 13 Participants
Phase 2 N=30 Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
Phase 2 N=12 Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
Fibrous Dysplasia Of Bone
Primary: Proportion of Participants With Serum Phosphate Levels Within the Target Range at Week 48 — 1 Proportion of participant
Phase 2 N=13 Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
X-Linked Hypophosphatemia
Primary: Change From Baseline at Week 40 in Serum Phosphorus — 0.96 mg/dL — p=< 0.0001
Phase 2 N=20 Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
X-Linked Hypophosphatemia
Primary: Number of Participants With Adverse Events (AEs), Treatment Emergent AEs (TEAEs), Serious AEs (SAEs), and AEs Leading to Discontinuation or Death — 20; 20; 12; 9…
Phase 3 N=61 Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
X-Linked Hypophosphatemia
Primary: Radiographic Global Impression of Change (RGI-C) Global Score at Week 40 — 0.77; 1.92 score on a scale — p=< 0.0001
Phase 2 N=19 Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
Hypophosphatasia
Primary: Change From Baseline to Week 24 for Plasma Pyridoxal-5' Phosphate (PLP) — -254.96; -564.27; 3.13; -397.72 ng/mL — p=0.0285
Phase 4 N=10 Examining the Effect of Burosumab on Muscle Function
X-linked Hypophosphatemia
Primary: Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate — 9.41 umol/g/min — p=0.4147
Phase 3 N=69 Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Hypophosphatasia
Primary: Effect of Asfotase Alfa Treatment on Skeletal Manifestations of Hypophosphatasia (HPP) — 2.00 scores on a scale
Phase 2 N=52 Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
X-linked Hypophosphatemia
Primary: Change From Baseline in RSS Total Score Over Time — -1.06; -0.73; -1.00; -0.84 score on a scale — p=< 0.0001
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Phase 1 N=15 Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
Hypophosphatasia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 5; 4; 0 Participants
Phase 3 N=51 A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)
Hypoparathyroidism
Primary: Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) — 13; 48 Participants
Phase 2 N=27 Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Hypoparathyroidism
Primary: Serum Calcium Level — 2; 1.92 mmol/liter
Phase 3 N=124 Use of NPSP558 in the Treatment of Hypoparathyroidism
Hypoparathyroidism
Primary: The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24. — 2.5; 54.8 percentage of participants — p=<0.001
N/A N=48 A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Hypophosphatasia (HPP)
Primary: Survival — 270.5 days
Phase 3 N=62 HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism
Hypoparathyroidism
Primary: Change in Dose of Calcium Supplementation — 37 percent change in dose
Phase 4 N=9 Vitamin D Repletion in Primary Hyperparathyroidism
Primary Hyperparathyroidism · Vitamin D Deficiency
Primary: Serum Parathyroid Hormone (PTH) Level
Phase 2 N=7 A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Autosomal Dominant Hypocalcemia (ADH)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 1 participants
N/A N=20 Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism
Secondary Hyperparathyroidism
Primary: The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours — 40.6; 46.2; 39.8; 58.8 pg/ml — p=0.1
Phase 4 N=1 A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)
Epidermal Nevus Syndrome
Primary: The Participant Will Achieve Normal Age-adjusted Phosphorous Levels as Tested by Fasting Serum Lab Values — 0.8; 1.2; 1.3; 1.1 mg/dl
Phase 2 N=12 Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Hypophosphatasia
Primary: Maximum Percent Change From Baseline in Extracellular Inorganic Pyrophosphate (PPi) — -36.46; -77.31; -56.88 percent change — p=0.0005
N/A N=39 Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
N/A N=32 Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
Hypophosphatasia (HPP)
Primary: Radiographic Global Impression of Change - RGI-C — 0.33 units on a scale — p=0.0755